**Name of Journal:** World Journal of Gastroenterology

**Manuscript NO: 37061**

**Manuscript Type: LETTER TO EDITOR**

**Silymarin: An option to treat non-alcoholic fatty liver disease**

Colica C *et al*. Silymarin and non-alcoholic fatty liver

Carmela Colica, Luigi Boccuto, Ludovico Abenavoli

**Carmela Colica,** CNR, IBFM UOS of Germaneto, University “Magna Graecia”, Catanzaro 88100, Italy

**Luigi Boccuto,** Research Department, Greenwood Genetic Center, School of Health Research, Clemson University, Greenwood 29646, United States

**Ludovico Abenavoli,** Department of Health Sciences, University Magna Græcia, Campus Germaneto, Viale Europa, Catanzaro 88100, Italy

**ORCID number:** Carmela Colica (0000-0001-6424-1223);Antonino De Lorenzo (0000-0001-6524-4493); Ludovico Abenavoli (0000-0002-5922-1524).

**Author contributions:** Colica C and Abenavoli L performed research of literature data and wrote the paper; Boccuto L revised the paper.

**Conflict-of-interest statement:** Authors declares no conflict of interest related to this publication.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to**: **Ludovico Abenavoli MD, PhD, Associate Professor,** Department of Health Sciences, University Magna Græcia, Campus Germaneto, Viale Europa - Germaneto, Catanzaro 88100, Italy. [l.abenavoli@unicz.it](mailto:l.abenavoli@unicz.it)

**Telephone:** +39-961-3697113

**Fax:** +39-961-754220

**Received:** November 8, 2017

**Peer-review started:** November 9, 2017

**First decision:** November 21, 2017

**Revised:** November 27, 2017

**Accepted:** December 5, 2017

**Article in press:**

**Published online:**

**Abstract**

We have read with a great interest the review published by Singh *et al*., on the treatment options in alcoholic and non-alcoholic fatty liver disease, including various new targeted therapies that are currently under investigation. Recently, we described the health effects of the Mediterranean diet associated to an antioxidant complex rich in silymarin, to improve in overweight patients anthropometric parameters, glucose and lipid metabolism and intra-hepatic fat accumulation.

**Key words**: Non-alcoholic fatty liver disease; Mediterranean diet; Antioxidant; Silymarin

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Supplementation of silymarin in association with an hypocaloric diet and physical activity, can be a correct approach to treat patients with non-alcoholic fatty liver disease in clinical practice.

Colica C, Boccuto L, Abenavoli L. Silymarin: An option to treat non-alcoholic fatty liver disease**.** *World J Gastroenterol* 2017; In press

**TO THE EDITOR**

We read with great interest the recent review by Singh *et al*[1] on the treatment options in alcoholic and non-alcoholic fatty liver disease (NAFLD), including various new targeted therapies that are currently under investigation. In the last decades the diagnosis of NAFLD was increasingly evoked in clinical practice, with a worldwide spread of NAFLD, with an estimated prevalence between 25%-30% of general population, not only in Western world but also in urban area of developing Countries[2]. NAFLD is an umbrella term that includes different clinical pictures ranged from simple fat accumulation to steato-hepatitis, fibrosis, cirrhosis and its complications. Central obesity, dyslipidemia, insulin resistance, and diabetes in a context of metabolic syndrome are the risk factors largely associated to the development and progression of NAFLD[3]. Recently, studies on the mechanisms involved in the pathogenesis of NAFLD, highlight the role of genetic polymorphisms enhancing oxidative stress, pro-inflammatory cytokines production and disequilibrium in the glucose and lipid metabolism[4]. The standard of care to treat NAFLD, described by international guidelines, is focused on lifestyle modifications and in particular on starting a healthy diet and increasing physical exercise. However, no drugs are currently approved to treat NAFLD and its secondary complications by regulatory agencies[5]. Reactive oxygen species production, including superoxide radical, hydroxyl radical, hydrogen peroxide, and lipid peroxide radicals, are involved in the pathogenesis and progression of NAFLD, in a multi-step process[6]. *Silybum marianum*, commonly known as Milk Thistle (MT), family of Asteraceae/Compositae, has been used since the time of ancient physicians, to treat liver diseases[7]. The active complex of MT is a lipophilic extract from the seeds of the plant and is composed of four isomer flavonolignans, collectively known as silymarin. Several pre-clinical and clinical studies have been carried out on silymarin and silibinin, its predominant and most active component. It has been described that silymarin possesses anti-oxidant, anti-inflammatory, and anti-ﬁbrotic properties. Our study group have been reported in a randomized study, the health effects of a hypocaloric Mediterranean diet in association with an antioxidant formulation with silymarin, on liver damage, glucose metabolism and anthropometric parameters in NAFLD overweight patients[8]. Data on the effects of silymarin in patients with NAFLD are limited. However, some studies showed that treatment with silymarin has been associated with an improvement of the oxidative profile, due to the ability of silymarin to inhibit the production of pro-inflammatory cytokines[9]. In addition, our data can be explained by the effectiveness of the diet associated to silymarin to reduce the extent of fat infiltration in the hepatocytes and to modulate the mitochondrial function.

In accordance with the paper by Singh *et al*[1], we conclude that new therapeutic targets are now under investigation for NAFLD. In this context, on the basis of our experience we support the role of silymarin, in association with lifestyle changes, to treat NAFLD patients, considering that it offers similar effects than some of the drugs listed by Singh *et al*[1] in terms of anti-oxidant (*e.g.,* NOX-1/4 inhibitors), anti-fibrotic (*e.g.,* galectin-3 antagonists, simtuzumab) and anti-inflammatory (*e.g.,* sirtuins) properties, but with considerably lower side effects.

**REFERENCES**

1 **Singh S**, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. *World J Gastroenterol* 2017; **23**: 6549-6570 [PMID: 29085205 DOI: 10.3748/wjg.v23.i36.6549]

2 **Masarone M**, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. *Rev Recent Clin Trials* 2014; **9**: 126-133 [PMID: 25514916 DOI: 10.2174/1574887109666141216111143]

3 **Abenavoli L**, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. *World J Gastroenterol* 2016; **22**: 7006-7016 [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006]

4 **Boccuto L**, Abenavoli L. Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. *Ann Hepatol* 2017; **16**: 490-500 [PMID: 28612750 DOI: 10.5604/01.3001.0010.0274]

5 **European Association for the Study of the Liver (EASL).**; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; **64**: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]

6 **Abenavoli L**, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. *Phytother Res* 2010; **24**: 1423-1432 [PMID: 20564545 DOI: 10.1002/ptr.3207]

7 **Colica C**, Di Renzo L, Trombetta D, Smeriglio A, Bernardini S, Cioccoloni G, Costa de Miranda R, Gualtieri P, Sinibaldi Salimei P, De Lorenzo A. Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial. *Oxid Med Cell Longev* 2017; **2017**: 2473495 [PMID: 28855976 DOI: 10.1155/2017/2473495]

8 **Abenavoli L**, Greco M, Nazionale I, Peta V, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. *Expert Rev Gastroenterol Hepatol* 2015; **9**: 519-527 [PMID: 25617046 DOI: 10.1586/17474124.2015.1004312]

9 **Federico A**, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. *Molecules* 2017; **22**: [PMID: 28125040 DOI: 10.3390/molecules22020191]

**P-Reviewer:** Hamaguchi M **S-Editor:** Chen K **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0